Efficacy of metamizole to prevent kidney injury after renal-ischaemic reperfusion injury in Wistar rats

Abstract

Background: Renal ischemia-reperfusion injury (RIRI) is a common kidney procedure complication due to temporary blood flow interruption, leading to kidney injuries. This study aimed to analyze the effect of metamizole on the levels of IL-18, NGAL, Myeloperoxidase (MPO), and histopathological changes in rats with RIRI. Materials and Methods: Animal pre-clinical design study was used. Thirty-two male wistar rats (Rattus norvegicus) were divided into four groups: negative control, positive control, M100, and M200. Blood samples were collected by intracardiac puncture, followed by bilateral nephrectomy and analyzed histopathologically. Results: Significant difference in IL-18 levels between positive control vs negative control (114.1 + 12.07 vs 94.0 + 11.4; P = 0.019) and positive control vs M100 (114.1 + 12.07 vs 86.9 + 8.34; P = 0.007). There was no difference in NGAL. M100 group had the lowest serum MPO levels (14.78+2.01), there was a significant difference in MPO levels in all pairwise analyses. There was a difference in cumulative EGTI scores among the study groups (positive 10.5 (8 – 11) vs. negative 9 (7-10) vs. M100 9 (7 – 10) vs. M200 9 (7 – 11); P = 0.021) Conclusion: Metamizole 100 mg/kgBW can reduce IL-18 and MPO levels in RIRI, giving more optimal results without affecting NGAL levels. Metamizole administration can reduce cumulative EGTI scores in RIRI, both at doses of 100 mg/kgBW and 200 mg/kgBW. This study shows that Metamizole can be used to prevent kidney injury caused by RIRI. IL-18 and MPO can be biomarkers in predicting kidney injury in RIRI.